ResMed (RMD) Q4 2025 10-Q Quarterly Report
Filed: Jan 30, 2026Period ending Dec 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR ResMed (RMD) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Jan 30, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ResMed Q4 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $1.423B for Q2 FY2025, up 11% YoY from $1.282B in Q2 FY2024; Sleep and Breathing Health segment up 12%, Residential Care Software up 7%
- • Gross margin 61.8% in Q2 FY2025 vs 58.6% YoY; operating expenses increased, SG&A 19.6% of revenue vs 18.8% YoY, R&D at 6.4% vs 6.3%
- • Best performing: Masks and other products revenue up 16% to $529.7M; worst performing: Residential Care Software with slower 7% growth
- • Cash and cash equivalents rose to $1.417B at Dec 31, 2025 from $1.209B at June 30, 2025; operating cash flow $797.1M for six months up $162.9M YoY; treasury stock repurchases $325M
- • Management cites continued growth driven by new product AirSense 11, expects ongoing innovation; notes global minimum tax impact on income tax rate increase to 20.9% for quarter; expects sufficient liquidity for next 12 months
Risk Factors
- • No new or changed risk factors since 10-K for fiscal year ended June 30, 2025
- • Continued exposure to product liability risks from medical device use as previously disclosed
- • Ongoing compliance risk with evolving global healthcare regulations, including FDA and EU MDR standards
- • Market risk from competitive pressure in sleep apnea device segment impacting near-term sales growth
- • Foreign currency exchange fluctuations affecting revenue as approximately 40% of sales are international
ResMed Q4 2025 Quarterly FinancialsXBRL
Revenue
$1.4B
▲ +11.0% YoY▲ +6.5% QoQ
Net Income
$393M
▲ +13.9% YoY▲ +12.6% QoQ
Net Margin
27.6%
▲ +71bp YoY▲ +150bp QoQ
Source: XBRL data from ResMed Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other ResMed Quarterly Reports
Get deeper insights on ResMed
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.